LAPP as a regulator of glucose homeostasis and pancreatic hormone secretion (review)

International Journal of Molecular Medicine

Volumn 3, Issue 6, 1999, Pages 577-584

  Karlsson, Ella ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

cell; Diabetes; Glucose homeostasis; Insulin; Islet amyloid polypeptide; Pancreatic islet

Indexed keywords

AMYLIN; AMYLIN RECEPTOR; AMYLOID; GLUCOSE; PANCREAS HORMONE; RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL; DIABETES MELLITUS; HUMAN; INSULIN RESISTANCE; METABOLISM; MOLECULAR GENETICS; OBESITY; PANCREAS; PHYSIOLOGY; REVIEW; SECRETION; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; AMYLOID; ANIMALS; DIABETES MELLITUS; GLUCOSE; HUMANS; INSULIN RESISTANCE; MOLECULAR SEQUENCE DATA; OBESITY; PANCREAS; PANCREATIC HORMONES; RECEPTORS, PEPTIDE; TISSUE DISTRIBUTION;

EID: 0033146803     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (142)

1. Opie EL: On the regulation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus. J Exp Med 5: 397-428, 1900.
2. Westermark P, Wernstedt C, Wilander E and Sletten K: A novel peptide in the calcitonin gene related peptidc family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140: 827-831, 1986.
3. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD and Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropcptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84: 3881-3885, 1987.
4. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB and Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84: 8628-8632, 1987.
5. O'Brien TD, Butler PC, Westermark P and Johnson KH: Islet amyloid polypeptide: a review of its biology and potential role in the pathogcnesis of diabetes mellitus. Vet Pathol 30: 317-332, 1993.
6. Betsholtz C, Christmanson L, Gebre-Medhin S and Westermark P: Islet amyloid polypeptide - hen or egg in type 2 diabetes pathogenesis? Acta Oncol 32: 149-154, 1993.
7. Clark A, Charge SB, Badman MK and De Koning EJ: Islet amyloid in type 2 (non-insulin-dependentj diabetes. APMIS 104: 12-18, 1996.
8. Clark A, Charge SB, Badman MK, MacArthur DA and De Koning EJ: Islet amyloid polypeptide: actions and role in the pathogenesis of diabetes. Biochem Soc Trans 24: 594-599, 1996.
9. Westermark P: Islet pathology of non-insulin-dependent diabetes mellitus (NIDDM). Diabct Med 13: S46-S48, 1996.
10. Kahn SE, Andrikopoulos S and Verchere CB: Islet amyloid. A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48: 241-253, 1999.
11. Badman MK, Shennan KIJ, Jermany JL, Docherty K and Clark A: Processing of proislet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378: 227-231, 1996.
12. Cooper GJ, Willis AC and Leighton B: Amylin hormone. Nature 340: 272, 1989.
13. Betsholtz C, Christmansson L, Engström U, Rorsman F, Sncnsson V, Johnson KH and Westermark P: Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explaines differences in islet amyloid formation between species. FEBS Lett 251: 261-264, 1989.
14. Betsholtz C, Christmansson L, Engström U, Rorsman F, Jordan K, O'Brian TD, Murtaugh M, Johnson KH and Westermark P: Structure of cat islet amyloid polypeptide and identification of aminoacid residues of potential significance for islet amyloid formation. Diabetes 39: 118-122, 1990.
15. Westermark P, Engström U, Johnson KH, Westermark GT and Betsholtz C: Islet amyloid polypeptide: pinpointing aminoacid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87: 5036-5040, 1990.
16. Pittner RA, Albrandt K, Beaumont K, Gaeta LS, Koda JE, Moore CX, Rittenhouse J and Rink TJ: Molecular physiology of amylin. J Cell Biochem 55 (Suppl): 19-28, 1994.
17. Nakazato M, Miyazato M, Asai J, Mitsukawa T, Kangawa K, Matsuo H and Matsukura S: Islet amyloid polypeptide, a novel pancreatic peptide, is a circulating hormone secreted under glucose stimulation. Biochem Biophys Res Commun 169: 713-718, 1990.
18. Nakazato M, Asai J, Miyazato M, Matsukura S, Kangawa K and Matsuo H: Isolation and identification of islet amyloid poly-peptide in normal human pancreas. Regul Pept 31: 179-186, 1990.
19. Wang ZL, Bennet WM, Ghatei MA, Byfield PGH, Smith DM and Bloom SR: Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 42: 330-335, 1993.
20. Percy AJ, Trainor DA, Rittenhouse J, Phelps J and Koda JE: Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42: 576-585, 1996.
21. Cooper GJ, Leighton B, Willis AC and Day AJ: The amylin superfamily: a novel grouping of biologically active polypeptides related to the insulin A-chain. Prog Growth Factor Res 1: 99-105, 1989.
22. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H and Eto T: Adrenomedullin: a novel hypotensive peptide from human phaeochromacytoma. Biochem Biophys Res Commun 192: 553-560, 1993.
23. Clark A, Edwards CA, Ostle LR, Sutton R, Rothbard JB, Morris JF and Turner RC: Localisation of islet amyloid peptide in lipofuscin bodies and secretory granulas of human B-cells and in islets of typc-2 diabetic subjects. Cell Tissue Res 257: 179-185, 1989.
24. Ahrén B and Sundler F: Localization of calcitonin gene-related peptide and islet amyloid polypeptide in the rat and mouse pancreas. Cell Tissue Res 269: 315-322, 1992.
25. De Vroede M, Foriers A, van de Winkel M, Madsen O and Pipeleers D: Presence of islet amyloid polypeptide in rat islet B and D cells determines parallellism and dissociation between rat pancreatic islet amyloid polypeptide and insulin content. Biochem .Biophys Res Commun 182: 886-893, 1992.
26. Rindi G, Terenghi G, Westermark P, Westermark G, Moscoso G and Polak JM: Islet amyloid polypeptide in proliferating pancreatic B cells during development, hyperplasia, and neoplasia in humans and mice. Am J Pathol 138: 1321-1334, 1991.
27. In't Veld PA, Zhang F, Madsen OD and Klöppel G: Islet amyloid polypeptide immunoreactivity in human fetal pancreas. Diabetologia 35: 272-276, 1992.
28. Toshimori HR, Narita R, Nakazato M, Asai J, Mitsukawa T, Kangawa K, Matsuo H and Matsukura S: Islet amyloid polypeptide (IAPP) in the gastrointestinal tract and pancreas of man and rat. Cell Tissue Res 262: 401-406, 1990.
29. Mulder H, Lindh AC, Ekblad E, Westermark P and Sundler F: Islet amyloid polypeptide is expressed in endocrine cells of the gastric mucosa in the rat and mouse. Gastroenterology 107: 712-719, 1994.
30. Femer GJ, Pierson AM, Jones PM, Bloom SR, Girgis SI and Legon S: Expression of the rat amylin (IAPP/DAP) gene. J Mol Endocrinol3:Rl-R4, 1989.
31. Nicholl CG, Bhatavdekar JM, Mak J, Girgis SI and Legon S: Extra-pancreatic expression of the rat islet amyloid polypeptide (amylin) gene. J Mol Endocrinol 9: 157-163, 1992.
32. Mulder H, Leckström A, Uddman R, Ekblad E, Westermark P and Sundler F: Islet amyloid polypeptide (amylin) is expressed in sensory neurons. J Neurosci 15: 7625-7632, 1995.
33. Chance WT, Balasubramaniam A, Zhang FS, Wirhalawansa SJ and Fischer JE: Anorexia following the intrahypothalamic administration of amylin. Brain Res 539: 352-354, 1991.
34. Fan L, Westermark G, Chan SJ and Steiner DF: Altered gene structure and tissue expression of islet amyloid polypeptide in the chicken. Mol Endocrinol 8: 713-721, 1994.
35. Galeazza MT, O'Brien TD, Johnson KH and Seybold VS: Islet amyloid polypeptide (IAPP) competes for two binding sites of CGRP. Peptides 12: 585-591, 1991.
36. Bhogal R, Smith DM and Bloom SR: Investigation and characterization of binding sites for islet amyloid polypeptide in rat membranes. Endocrinology 130: 906-913, 1992.
37. Wookey PJ, Tikellis C, Du HC, Qin HF, Sexton PM and Cooper ME: Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin. Am J Physiol 39: F289-F294, 1996.
38. Christmanson L, Westermark P and Betsholtz C: Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor. Biochem Biophys Res Commun 205: 1226-1235, 1994.
39. Sexton PM, Houssami S, Brandy CL, Myers DE and Findlay DM: Amylin is an agonist of the renal porcine calcitonin receptor. Endocrinology 134: 2103-2107, 1994.
40. Morley JE and Flood JF: Amylin decreases food intake in mice. Peptides 12: 865-869, 1991.
41. Bouali SM, Wimalawansa SJ and Jolicoeur FB: In vivo central actions of rat amylin. Regul Pept 56: 167-174, 1995.
42. Chance WT, Balasubramaniam A, Stallion A and Fischer JE: Anorexia following the systemic injection of amylin. Brain Res 607: 185-188, 1993.
43. Morley JE, Flood JF, Horowitz M, Morley PMK and Walter MJ: Modulation of food intake by periferally administered amylin. Am J Physiol 267: R178-R184, 1994.
44. Arnelo U, Permert J, Adrian TE, Larsson J, Westermark P and Reidelberger RD: Chronic infusion of islet amyloid poly-peptide causes anorexia in rats. Am J Physiol 40: R1654-R1659, 1996.
45. Young AA, Gedulin B, Vine W, Percy A and Rink TJ: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38: 642-648, 1995.
46. 2, amylin, cholesystokinin, and other possible regulators of nutrient uptake. Metabolism 45: 1-3, 1996.
47. Ahrén B, Oosterwijk C, Lips CJ and Hoppener JW: Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. Diabetologia 41: 1374-1380, 1998.
48. Young A: Role of amylin in nutrient intake-animal studies. Diabet Med 14 (Suppl 2): S14-S18, 1997.
49. Young AA, Mott DM and Cooper GJ: Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 281: 149-151, 1991.
50. Cooper GJ: Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev 15: 163-202, 1994.
51. Leighton B and Cooper GJ: Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335: 632-635, 1988.
52. Leighton B and Foot E: The effects of amylin on carbohydrate metabolism in skeletal muscle in vitro and in vivo. Biochem J 269: 19-23, 1990.
53. Deems RO, Deacon RW and Young DA: Amylin activates glycogen phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism. Biochem Biophys Res Commun 174: 716-720, 1991.
54. Lawrence JC and Zhang JN: Control of glycogen synthase and phosphorylase by amylin in rat skeletal muscle-hormonal effects on the phosphorylation of phosphorylase and on the distribution of phosphate in the synthase subunit. J Biol Chem 269: 11595-11600, 1994.
55. Frontoni S, Choi SB, Banduch D and Rossetti L: In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 40: 568-573, 1991.
56. Castle AL, Kuo CH, Han DH and Ivy JL: Amylin-mediated inhibition of insulin-stimulated glucose transport in skeletal muscle. Am J Physiol 275: E531-E536, 1998.
57. Rosetti L, Farrace S, Choi SB, Giaccari A, Sloan L, Frontoni S and Katz MS: Multiple metabolic effects of CGRP in conscious rats: role of glycogen synthase and phosphorylase. Am J Physiol 264: E1-E10, 1993.
58. Young DA, Deems RO, Deacon RW, Mclntosh RH and Foley JE: Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol 259: E457-E461, 1990.
59. Molina JM, Cooper GJ, Leighton B and Olefsky JM: Induction of insulin resistance in vivo by amylin and calcitonin generelated peptide. Diabetes 39: 260-265, 1990.
60. Wilding JP, Khandan Nia N, Bennet WM, Gilbey SG, Beacham J, Ghatei MA and Bloom SR: Lack of acute effect of amylin (islet associated peptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 37: 166-169, 1994.
61. Zierath JR, Galuska D, Engström A, Johnson KH, Betsholtz C, Westermark P and Wallberg-Henriksson H: Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in in vitro incubated human muscle strips. Diabetologia 35: 26-31, 1992.
62. Pittner RA, Wolfwlopez D, Ypung AA and Rink TJ: Amylin and adrenaline have no direct effect on glucose transport in isolated soleus muscle. FEBS Lett 365: 98-100, 1995.
63. Koopmans SJ, van Mansfeld AD, Jansz HS, Krans HM, Radder KJ, Frolich M, De Boer SF, Kreutter DK, Andrews GC and Maassen JA: Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues. Diabetologia 34: 218-224, 1991.
64. Young AA, Rink TJ and Wang MW: Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat. Life Sci 52: 1717-1726, 1993.
65. Ciaraldi TP, Goldberg M, Odom R and Stolpe M: In vitro effects of amylin on carbohydrate metabolism in liver cells. Diabetes 41: 975-981, 1992.
66. Stephens TW, Heath WF and Hermeling RN: Presence of liver CGRP/amylin receptors in only nonparenchymal cells and absence of direct regulation of rat liver glucose metabolism by CGRP/amylin. Diabetes 40: 395-400, 1991.
67. Morishita T, Yamaguchi A, Yamatani T, Nakamura A, Arima N, Yamashita Y, Nakata H, Fujita T and Chiba T: Effects of islet amyloid polypeptide (amylin) and calcitonin gene-related peptide (CGRP) on glucose metabolism in the rat. Diabetes Res Clin Pract 15: 63-69, 1992.
68. Barakat A, Rosselin G and Marie JC: Characterization of specific calcitonin gene-related peptide receptors present in hamster pancreatic beta cells. Biosci Rep 13: 221-231, 1993.
69. Silvestre RA, Salas M, Dégano P, Pefro E and Marco J: Reversal of the inhibitory effects of calcitonin gene-related peptide (CGRP) and amylin on insulin secretion by the 8-37 fragment of human CGRP. Biochem Pharmacol 45: 2343-2347, 1993.
70. Ahrén B and Pettersson M: Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas. Int J Pancreatol 6: 1-15, 1990.
71. Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Macrae AD and Bloom SR: Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenious glucose in man. J Clin Endocrinol Metab 74: 1032-1035, 1992.
72. Pettersson M, Ahrén B, Böttcher G and Sundler F: Calcitonin gene-related peptide: occurence in pancreatic islets in the mouse and rat and inhibition of insulin secretion in the mouse. Endocrinology 119: 865-869, 1986.
73. Ishizuka J, Greeley GH, Cooper CW and Thomson JC: Effect of calcitonin gene-related peptide on glucose and gastric inhibitory polypeptide-stimulated insulin release from cultured newborn and adult rat islet cells. Regul Pept 20: 73-82, 1988.
74. Fujimura M, Greeley GH, Hancock MB, Alwmark A, Santos A, Cooper CW, Reumont KJ, Ishizuka J and Thompson JC: Colocalization of calcitonin gene-related peptide and somatostatin in pancreatic islet cells and inhibition of insulin secretion by calcitonin gene-related peptide in the rat. Pancreas 3: 49-52, 1988.
75. Ahrén B, Mårtensson H and Nobin A: Effects of calcitonin gene-related peptide (CGRP) on islet hormone secretion in the pig. Diabetologia 30: 354-359, 1987.
76. Hermansen K and Ahrén B: Dual effects of calcitonin generelated peptide on insulin secretion in the perfused dog pancreas. Regul Pept 27: 149-157, 1990.
77. Ar'Rajab A and Ahren B: Effects of amidated rat islet amyloid polypeptide on glucose stimulated insulin secretion in vivo and in vitro in mice. Eur J Pharmacol 192: 443-445, 1991.
78. Dégano P, Silvestre RA, Salas M, Peíro E and Marco J: Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas. Regul Pept 43: 91-96, 1993.
79. Fürnsinn C, Leuvenink H, Roden M, Nowotny P, Schneider B, Rohac M, Fieber T, Clodi M and Waldhäusl W: Islet amyloid polypeptide inhibits insulin secretion in conscious rats. Am J Physiol 267: E300-E305, 1994.
80. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H and Yoshida S: Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 160: 961-967, 1989.
81. Silvestre RA, Peíro E, Dégano P, Miralles P and Marco J: Inhibitory effect of rat amylin on the insulin response to glucose and arginin in the perfused rat pancreas. Regul Pept 31: 23-31, 1990.
82. Wagoner PK, Chen C, Worley JF, Dukes ID and Oxford GS: Amylin modulates beta-cell glucose sensing via effects on stimulus-secretion coupling. Proc Natl Acad Sci USA 90: 9145-9149, 1993.
83. Wang F, Adrian TE, Westermark GT, Ding X, Gasslander T and Permert J: Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. Am J Physiol 276: E19-E24, 1999.
84. Inoue K, Hiramatsu S, Hisatomi A, Umeda F and Nawata H: Hypersecretion of amylin from the perfused pancreas of genetically obese (fa/fa) rats and its alteration with aging. Metabolism 42: 654-658, 1993.
85. Pefro E, Dégano P, Silvestre RA and Marco J: Inhibition of insulin release by amylin is not mediated by changes in somatostatin output. Life Sci 49: 761-765, 1991.
86. Kogire M, Ishizuka J, Thompson JC and Greeley GH Jr: Inhibitory action of islet amyloid polypeptide and calcitonin gene-related peptide on release of insulin from the isolated perfused rat pancreas. Pancreas 6: 459-463, 1991.
87. Silvestre RA, Salas M, Garcia-Hermida O, Fontela T, Dégano P and Marco J: Amylin (islet amyloid polypeptide) inhibition of insulin release in the perfused rat pancreas: implication of the adenylate cyclase/cAMP system. Regul Pept 50: 193-199, 1994.
88. Salas M, Silvestre RA, Garcia-Hermida O, Fontela T, Rodriguez-Gallardo J and Marco J: Inhibitory effect of amylin (islet amyloid polypeptide) on insulin response to non-glucose stimuli. Study in the perfused rat pancreas. Diabetes Metab 21: 269-273, 1995.
89. Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Törnell J, Sundler F, Westermark P, Ahrén B and Betsholtz C: Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250: 271-277, 1998.
90. Nagamatsu S, Carroll RJ, Grodsky GM and Steiner DF: Lack of islet amyloid polypeptide regulation of insulin biosynthesis or secretion in normal rat islets. Diabetes 39: 871-874, 1990.
91. Nagamatsu S, Nishi M and Steiner DF: Effects of islet amyloid polypeptide (IAPP) on insulin biosynthesis or secretion in rat islets and mouse beta TC3 cells. Biosynthesis of IAPP in mouse beta TC3 cells. Diabetes Res Clin Pract 15: 49-55, 1992.
92. O'Brien TD, Westerrnark P and Johnson KH: Islet amyloid polypeptide (IAPP) does not inhibit glucose-stimulated insulin secretion from isolated perfused rat pancreas. Biochem Biophys Res Commun 170: 1223-1228, 1990.
93. Petterson M and Ahrén B: Failure of islet amyloid polypeptide to inhibit basal and glucose-stimulated insulin secretion in model experiments in mice and rats. Acta Physiol Scand 138: 389-394, 1990.
94. Tedstone AE, Nezzer T, Hughes SJ, Clark A and Matthews DR: The effect of islet amyloid polypeptide (IAPP) and calcitonin gene-related peptide on glucose removal in the anaesthetized rat and on insulin secretion from rat pancreatic islets in vitro. Biosci Rep 10: 339-345, 1990.
95. Broderick CL, Brooke GS, Di Marchi RD and Gold G: Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets. Biochem Biophys Res Commun 177: 932-938, 1991.
96. Barakat A, Skoglund G, Boissard C, Rosselin G and Marie JC: Calcitonin gene-related peptide and islet amyloid polypeptide stimulate insulin secretion in RINmSF cells through a common receptor coupled to a generation of cAMP. Biosci Rep 14: 1-13, 1994.
97. Fehmann HC, Weber V, Göke R, Göke B, Eissele R and Arnold R: Islet amyloid polypeptide (IAPP; amylin) influences the endocrine but not the exocrine rat pancreas. Biochem Biophys Res Commun 167: 1102-1108, 1990.
98. Stridsberg M, Berne C, Sandler S, Wilander E and Oberg K: Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of islet amyloid polypeptidelike molecule. Diabetologia 36: 843-849, 1993.
99. Tokuyama T. Yagui K, Yamaguchi T, Huang CI, Kuramoto N, Shimada F, Miyazaki J, Horie H, Saito Y, Makino H and Kanatsuka A: Expression of human islet amyloid polypeptide/ amylin impairs insulin secretion in mouse pancreatic beta cells. Metabolism 46: 1044-1051, 1997.
100. Gedulin BR, Rink TJ and Young A A: Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46: 67-70, 1997.
101. Panagiotidis G, Salehi AA, Westermark P and Lundquist I: Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse. Diabetes Res Clin Pract 18: 167-171, 1992.
102. Kahn SE, D'Alessio DA, Schwanz MW, Fujimoto WY, Ensinck JW, Taborsky GJ and Porte DJ: Evidence of cosecretion of islet amyloid polypeptide and insulin by beta cells. Diabetes 39: 634-638, 1990.
103. Kautzky-VViller A, Tomaseth K, Pacini G, Clodi M, Ludvik B, Streu C, Waldhäusl W and Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37: 188-194, 1994.
104. De Koning EJP, Fleming KA, Gray DWR and Cark A: High prevalence of pancreatic islet amyloid in patients with end-stage renal failure on dialysis treatment. J Pathol 175: 253-258, 1995.
105. Kahn SE, Verchere CB, D'Alessio DA, Cook DL and Fujimoto WY: Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway. Diabetologia 36: 570-573, 1993.
106. Alam T, Chen L, Ogawa A, Leffert JD, Unger RH and Luskey KL: Coordinate regulation of amylin and insulin expression in response to hypoglycemia and fasting. Diabetes 41: 508-514, 1992.
107. Mulder H, Ahrén B and Sundler F: Islet amyloid polypeptide and insulin expression are regulated in parallel by glucose in vivo in rats. Am J Physiol 271: E1008-E1014, 1996.
108. Larsson H and Ahrén B: Effects of arginin on the secretion of insulin and islet amyloid polypeptide in humans. Pancreas 11: 201-205, 1995.
109. Stridsberg M, Sandler S and Wilander E: Cosecretion of islet amyloid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of beta-cell function. Regul Pept 45: 363-370, 1993.
110. Bell ET: Hyalinization of the islets of Langerhans in non-diabetic individuals. Am J Pathol 35: 801-805, 1959.
111. Howard CF Jr: Insular amyloidosis and diabetes mellitus in Macaco nigra. Diabetes 27: 357-364, 1978.
112. Johnson KH, Hayden DW, O'Brien TD and Westermark P: Spontaneous diabetes mellitus-islet amyloid complex in adult cats. Am J Pathol 125: 416-419, 1986.
113. Maloy AL, Longnecker DS and Greenberg ER: The relation of islet amyloid to the clinical type of diabetes. Hum Pathol 12: 917-922, 1981.
114. Palotay JL and Howard CF Jr: Insular amyloidosis in spontaneously diabetic nonhuman primates. Vet Pathol 19: 181-192, 1982.
115. Westermark P: Quantitative studies of amyloid in the islets of Langcrhans. Ups J Med Sci 77: 91-94, 1974.
116. Yano BL, Hayden DW and Johnson KH: Feline insular amyloid: association with diabetes mellitus. Vet Pathol 18: 621-627, 1981.
117. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhcgan RI, Matthews DR, Cooper GJ, Holman RR and Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9: 151-159, 1988.
118. Westermark P: Fine structure of islets of Langcrhans in insular amyloidosis. Virchows Arch (A) 359: 1-18, 1973.
119. Mirzabckov TA, Lin MC and Kagan BL: Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chcm 271: 1988-1992, 1996.
120. Lorenzo A, Razzaboni B, Weir GC and Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368: 756-760, 1994.
121. Janson J, Ashley RH, Harrison D, Mclntyre S and Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48: 491-506, 1999.
122. De Fronzo RA: Pathogcncsis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35: 389-397, 1992.
123. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M and Najo K: Plasma islet amyloid polypeptidc (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dcpendent) diabetic patients. Diabetologia 34: 129-132, 1991.
124. Hanabusa T, Kubo K, Oki C, Nakano Y, Okai K, Sanke T and Nanjo K: Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependcnt diabetes mellitus. Diabetes Res Clin Pract 15: 89-96, 1992.
125. O'Brien TD, Westermark P and Johnson KH: Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 40: 1701-1706, 1991.
126. Bretherton-Watt D, Ghatei MA, Legon S, Jamal H, Ferrier GJ, Girgis SI and Legon S: Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes. Diabetologia 32: 881-883, 1989.
127. MuIder H, Ahrén B, Stridsberg M and Sundler F: Nonparallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 38: 395-402, 1995.
128. Leckström A, Östenson CG, Efendic S, Amelo U, Permert J, Lundquist I and Westermark P: Increased storage and secretion of islet amyloid polypeptide relative to insulin in the spontaneously diabetic GK rat. Pancreas 13: 259-267, 1996.
129. Kautzky-Willer A, Thomaseth K, Clodi M, Ludvik B, Waldhäusl W, Präger R and Pacini G: Beta-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. Metabolism 45: 486-491, 1996.
130. Hou X, Ling Z, Quartier E, Foriers A, Shuit F, Pipellers D and van Schravendijk C: Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia 42: 188-194, 1999.
131. Karlsson E, Stridsberg M and Sandier S: Leptin regulation of islet amyloid polypeptide secretion from mouse pancreatic islets. Biochem Parmacol 56: 1339-1346, 1998.
132. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H and Matsukara S: Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and noninsulin dependent diabetes mellitus. Diabetes Res Clin Pract 15: 97-102, 1992.
133. Porte D Jr: Banting lecture: beta-cells in type II diabetes mellitus. Diabetes 40: 166-180, 1991.
134. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W and Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its cosecretion with insulin in humans. Diabeologia 34: 52-54, 1991.
135. Ogawa A, Harris V, McCorkle SK, Unger RH and Luskey KL: Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 85: 973-976, 1990.
136. Jamal H, Bretherton Watt D, Suda K, Ghatei MA and Bloom SR: Islet amyloid polypeptide-like immunoreactivity (amylin) in rats treated with dexamethasone and streptozotocin. J Endocrinol 126: 425-429, 1990.
137. Mulder H, Ahrén B and Sundler F: Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Mol Cell Endocrinol 114: 101-109, 1995.
138. Karlsson E, Stridsberg M and Sandler S: IAPP and insulin secretion from pancreatic islets isolated from non-obese diabetic (NOD) mice. Regul Pept 63: 39-45, 1996.
139. Clark A, Yon SM, De Koning EJ and Holman RR: Autoantibodies to islet amyloid polypeptide in diabetes. Diabet Med 8: 668-673, 1991.
140. Gorus FK, Sodoycs JC, Pipeleers DG, Keymeulen B, Foriers A and van Schravendijk CF: Detection of autoantibodies against amyloid polypeptide in human serum. Lack of association with type 1 (insulin-dependent) diabetes mellitus, or with conditions favouring amyloid deposition in islets. The Belgian Diabetes Registry. Diabetologia 35: 1080-1086, 1992.
141. Tuck AB and Wilkin TJ: Failure to detect autoantibodies to islet amyloid polypcptide in sera from type 1 diabetic patients. Diabet Med 9: 781, 1992.
142. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K and Pacini G: Amylin: history and overview. Diabet Med 14: S9-S13, 1997.